Royalty Pharma PLC (RPRX)
25.80
+0.10
(+0.37%)
USD |
NASDAQ |
Nov 18, 16:00
25.80
0.00 (0.00%)
After-Hours: 19:42
Royalty Pharma Debt to Equity Ratio: 1.107 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.107 |
| June 30, 2024 | 1.174 |
| March 31, 2024 | 0.9446 |
| December 31, 2023 | 0.9401 |
| September 30, 2023 | 0.9987 |
| June 30, 2023 | 1.134 |
| March 31, 2023 | 1.196 |
| December 31, 2022 | 1.264 |
| September 30, 2022 | 1.156 |
| June 30, 2022 | 1.179 |
| Date | Value |
|---|---|
| March 31, 2022 | 1.229 |
| December 31, 2021 | 1.228 |
| September 30, 2021 | 1.224 |
| June 30, 2021 | 1.016 |
| March 31, 2021 | 1.192 |
| December 31, 2020 | 1.207 |
| September 30, 2020 | 1.306 |
| June 30, 2020 | 1.422 |
| March 31, 2020 | 1.154 |
| December 31, 2019 | 1.022 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.9401
Minimum
Dec 2023
1.422
Maximum
Jun 2020
1.155
Average
1.176
Median
Debt to Equity Ratio Benchmarks
| Geron Corp | 0.2868 |
| Amicus Therapeutics Inc | 2.178 |
| Ionis Pharmaceuticals Inc | 1.930 |
| Arbutus Biopharma Corp | 0.00 |
| Syndax Pharmaceuticals Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 18.04B |
| Total Liabilities (Quarterly) | 7.784B |
| Shareholders Equity (Quarterly) | 6.870B |
| Current Ratio | 1.536 |
| Net Debt Paydown Yield | -0.76% |